Nitric oxide (Genosyl)

Other

Approvedregulatory verdict

Evidence outlook

Approved: Persistent Pulmonary Hypertension of the Newborn

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Other / comorbidity
NCT01265888 · Geno LLC
2011-03 – 2016-09 · Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
What this study did
NCT01165047 · Wake Forest University Health Sciences
2010-09 – 2011-09 · Pulmonary Arterial Hypertension
What this study did
NCT01092559 · Geno LLC
2010-10 – 2011-07 · Pulmonary Arterial Hypertension
What this study did

Competitive landscape

This drug's own stage for Persistent Pulmonary Hypertension of the Newborn: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nitric Oxide (Genosyl): this drugApprovedGas (inhaled, On-demand Generation)Soluble guanylyl cyclase (sGC)not yet gradedNo reviewed efficacy summary in this indication
Nitric Oxide (INOmax)ApprovedGas (inhaled)Nitric oxidenot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.